Literature DB >> 18754859

Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy.

Mayumi Ono1.   

Abstract

Both inflammation and angiogenesis are exacerbated by increased production of chemokines/cytokines, growth factors, proteolytic enzymes, proteoglycans, lipid mediators and prostaglandins. It has been reported that approximately 15-20% of all malignancies are initiated or exacerbated by inflammation. Initiation and progression of cancer are also closely linked to angiogenesis. Infiltration of macrophages is a dramatic and common feature of inflammation, angiogenesis and cancer, and has been recently highlighted in an attempt to develop novel strategies for treating cancer. The recruitment and infiltration of macrophages in the tumor microenvironment activates them to support the malignant progression of cancer cells, and these macrophages are called tumor-associated macrophages. In a model of experimental angiogenesis using mouse corneas, macrophages infiltrated tissue in response to inflammatory cytokines and produced chemokines and angiogenesis-promoting factors, such as vascular endothelial growth factor-A, interleukin-8, matrix metalloproteinases, prostanoids and reactive oxygen species. Moreover, in a cancer xenograft model, inflammatory stimuli by a representative inflammatory cytokine, interleukin-1beta, enhanced tumor growth and angiogenesis with infiltration and activation of macrophages. Co-culture of cancer cells with macrophages synergistically stimulated production of various angiogenesis-related factors when stimulated by the inflammatory cytokine. This inflammatory angiogenesis in both mouse cornea and a tumor model was mediated, in part, by activation of nuclear factor kappaB and activator protein 1 (Jun/Fos). Administration of either nuclear factor kappaB-targeting drugs or cyclooxygenase 2 inhibitors or depletion of macrophages could block both inflammatory angiogenesis and tumor angiogenesis. Thus, both inflammatory and angiogenic responses in tumor stroma could be targets for development of anticancer therapeutic drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18754859     DOI: 10.1111/j.1349-7006.2008.00853.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  141 in total

Review 1.  Protein biomarkers of ovarian cancer: the forest and the trees.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Future Oncol       Date:  2012-01       Impact factor: 3.404

Review 2.  EET signaling in cancer.

Authors:  Dipak Panigrahy; Emily R Greene; Ambra Pozzi; Dao Wen Wang; Darryl C Zeldin
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 3.  NRF2 and the Hallmarks of Cancer.

Authors:  Montserrat Rojo de la Vega; Eli Chapman; Donna D Zhang
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

4.  Wound healing delay after central venous access following DCF/VEGF-trap therapy.

Authors:  Charles Ferté; Christophe Massard; Christian Moldovan; Eric Desruennes; Yohann Loriot; Jean-Charles Soria
Journal:  Invest New Drugs       Date:  2009-02-17       Impact factor: 3.850

5.  Vastatin (the NC1 domain of human type VIII collagen a1 chain) is linked to stromal reactivity and elevated in serum from patients with colorectal cancer.

Authors:  Nicholas Willumsen; Lars Nannestad Jorgensen; Morten Asser Karsdal
Journal:  Cancer Biol Ther       Date:  2019-01-09       Impact factor: 4.742

Review 6.  Deconvoluting the obesity and breast cancer link: secretome, soil and seed interactions.

Authors:  Nikki A Ford; Kaylyn L Devlin; Laura M Lashinger; Stephen D Hursting
Journal:  J Mammary Gland Biol Neoplasia       Date:  2013-10-04       Impact factor: 2.673

7.  Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.

Authors:  Farzin Forooghian; Peter J Kertes; Kenneth T Eng; Elvira Agrón; Emily Y Chew
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-10       Impact factor: 4.799

8.  Prostaglandin E2 receptor EP1 phosphorylate CREB and mediates MMP2 expression in human cholangiocarcinoma cells.

Authors:  Bo Sun; Rong Rong; Hai Jiang; Hai Zhang; YiPin Wang; Xiaoming Bai; Min Zhang; Juan Ma; Shukai Xia; Wei Shu; Li Zhang; Jing Leng
Journal:  Mol Cell Biochem       Date:  2013-03-15       Impact factor: 3.396

Review 9.  Diabetes and cancer: Associations, mechanisms, and implications for medical practice.

Authors:  Chun-Xiao Xu; Hong-Hong Zhu; Yi-Min Zhu
Journal:  World J Diabetes       Date:  2014-06-15

10.  MicroRNAs: New players in cancer prevention targeting Nrf2, oxidative stress and inflammatory pathways.

Authors:  Chengyue Zhang; Limin Shu; Ah-Ng Tony Kong
Journal:  Curr Pharmacol Rep       Date:  2015-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.